$PASG News

Last published 5d ago

5d agoPASGTrading halt: Passage Bio, Inc. CS (PASG), Volatility trading pauseNasdaq Trading HaltsHalted 2026-11-06 09:37:17.036 ET, resumption quote 2026-11-06 09:37:17 ET, resumption trade none.
4mo agoPASGPassage Bio and Remix Therapeutics Announce Merger AgreementGlobeNewswireCombined company to operate as Remix Therapeutics and advance Remix’s pipeline of novel small molecule therapies designed to reprogram RNA processing and address disease drivers at their origin Remix’s lead program,
4mo agoPASGPassage Bio / Remix Therapeutics Merger Conference Call - PASSAGE BIO INCEarnings Call TranscriptsGood morning, and welcome to the PassageBio Remix Therapeutics Merger Agreement Announcement Conference Call. I would like to remind you that this call is being recorded for replay. I will now turn the conference call ov
6mo agoPASGPassage Bio Reports Updated Interim Data from upliFT-D Trial and Provides Regulatory and Corporate UpdatesGlobeNewswirePBFT02 administration resulted in improvements in two disease progression biomarkers, as compared to natural history, reducing brain atrophy and stabilizing plasma NfL levels FDA feedback from recent Type C meeting
8mo agoPASGPassage Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Recent Business HighlightsGlobeNewswireEnrolled first three FTD-GRN patients in Cohort 3 of ongoing upliFT-D study Treated first FTD-C9orf72 patient with Dose 2 PBFT02 in Cohort 4 of upliFT-D study On track to report updated interim safety and biomarker
8mo agoPASGPassage Bio to Participate in Upcoming Investor ConferencesGlobeNewswirePHILADELPHIA, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ:PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced
1y agoPASGPassage Bio Reports Third Quarter 2025 Financial Results and Provides Recent Business HighlightsGlobeNewswireActively enrolling Cohort 3 (FTD-GRN) and Cohort 4 (FTD-C9orf72) patients in ongoing upliFT-D study Aligned with the U.S. Food and Drug Administration (FDA) on an analytical approach to establish comparability of a
1y agoPASGPassage Bio to Present at Guggenheim Securities 2nd Annual Healthcare Innovation ConferenceGlobeNewswirePHILADELPHIA, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ:PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced
1y agoPASGPassage Bio to Participate in Chardan's 9th Annual Genetic Medicines ConferenceGlobeNewswirePHILADELPHIA, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ:PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced
1y agoPASGPassage Bio to Participate in H.C. Wainwright 27th Annual Global Investment ConferenceGlobeNewswirePHILADELPHIA, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ:PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced
1y agoPASGPassage Bio Reports Second Quarter 2025 Financial Results and Provides Recent Business HighlightsGlobeNewswireCompleted dosing of FTD-GRN Cohort 2 in upliFT-D study Reported updated interim data showing that PBFT02 continued to demonstrate robust, durable elevation in CSF PGRN levels and improvement in plasma NfL, a disease
1y agoPASGPassage Bio Announces 1-for-20 Reverse Stock SplitGlobeNewswirePHILADELPHIA, July 10, 2025 (GLOBE NEWSWIRE) -- Passage Bio, Inc. ("Passage Bio" or the "Company") (NASDAQ:PASG), a clinical-stage genetic medicines company focused on improving the lives of patients with
1y agoPASGPassage Bio Reports First Quarter 2025 Financial Results and Provides Recent Business HighlightsGlobeNewswireTreated first FTD-GRN patient with Dose 2 PBFT02 and enrolled second patient; several additional patients being evaluated for trial eligibility Announced presentation of process development data of a high
1y agoPASGPassage Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Recent Business HighlightsGlobeNewswireInterim data from Dose 1 PBFT02 demonstrated durable, elevated CSF PGRN and early evidence of reduction in plasma NfL levels, a disease progression biomarker, as compared to published natural history Enrolled first
1y agoPASGPassage Bio to Participate in Upcoming Investor ConferencesGlobeNewswirePHILADELPHIA, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ:PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced
1y agoPASGPassage Bio Announces Interim Data from upliFT-D Study in FTD-GRN and Provides Business UpdatesGlobeNewswirePBFT02 demonstrated durable, elevated CSF PGRN levels and early evidence of reduction in plasma NfL levels, a disease progression biomarker, compared to published natural history data Evaluating Dose 2, 50% lower than
1y agoPASGPassage Bio Reports Third Quarter 2024 Financial Results and Provides Recent Business HighlightsGlobeNewswireEnrolled 4 patients in Cohort 2 of the upliFT-D trial for FTD-GRN, with patient dosing advancing as planned; 12-month Cohort 1 and interim Cohort 2 data expected in 1H25 Updated interim data from Cohort 1 FTD-GRN
2y agoPASGPassage Bio to Present at Guggenheim Securities Healthcare Innovation ConferenceGlobeNewswirePHILADELPHIA , Nov. 06, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ:PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced
2y agoPASGPassage Bio Presents Preclinical and Interim Clinical Data for PBFT02 in FTD-GRN at the European Society of Gene & Cell Therapy (ESGCT) 31st Annual ConferenceGlobeNewswirePreclinical data demonstrated that an AAV1 vector achieved superior human progranulin levels in the CSF as compared to AAV5 and AAVhu68 (an AAV9 variant) Nonclinical data showed PBFT02 improved lysosomal histopathology
2y agoPASGPassage Bio to Present at Chardan's 8th Annual Genetic Medicines ConferenceGlobeNewswirePHILADELPHIA, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ:PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced
2y agoPASGPassage Bio to Present Positive Interim Data from Cohort 1 Patients with FTD-GRN in upliFT-D Study at 14th International Conference on Frontotemporal Dementias (ISFTD2024)GlobeNewswireInterim safety and biomarker data from the upliFT-D trial in FTD-GRN demonstrated that Dose 1 of PBFT02 achieved robust levels of CSF progranulin in all treated Cohort 1 patients; elevated CSF progranulin levels were
2y agoPASGPassage Bio Welcomes Tom Kassberg to Board of DirectorsGlobeNewswirePHILADELPHIA, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ:PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced
2y agoPASGPassage Bio to Present at H.C. Wainwright 26th Annual Global Investment ConferenceGlobeNewswirePHILADELPHIA, Aug. 30, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ:PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced
2y agoPASGPassage Bio Reports Second Quarter 2024 Financial Results and Provides Recent Business HighlightsGlobeNewswireEnrolled first FTD-GRN patient in Cohort 2 in upliFT-D trial Plan to present updated safety and biomarker data from Cohort 1 FTD-GRN patients treated with PBFT02 at 14th International Conference on Frontotemporal
2y agoPASGPassage Bio to Participate in Upcoming Investor ConferencesGlobeNewswirePHILADELPHIA, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ:PASG), a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced
2y agoPASGPassage Bio Out-licenses Three Pediatric Gene Therapy Programs to GEMMA Biotherapeutics and Enters New Research CollaborationGlobeNewswireGranted exclusive, worldwide rights for the development and commercialization of PBGM01 for GM1 gangliosidosis, PBKR03 for Krabbe disease, and PBML04 for metachromatic leukodystrophy to GEMMA Biotherapeutics, a new
2y agoPASGPassage Bio Announces Positive Feedback from FDA on Expansion of upliFT-D Trial of PBFT02 to Include FTD-C9orf72 PatientsGlobeNewswireAgency feedback from Type C meeting process supports the company's proposed clinical development plans to expand the upliFT-D trial to assess PBFT02 in FTD patients with C9orf72 gene mutations Plan to initiate
2y agoPASGPassage Bio to Present at Goldman Sachs 45th Annual Global Healthcare ConferenceGlobeNewswirePHILADELPHIA, June 05, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ:PASG), a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced
2y agoPASGPassage Bio Announces Recipient of Third Annual Tachi Yamada Scholarship AwardGlobeNewswirePHILADELPHIA, May 21, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ:PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced
2y agoPASGPassage Bio Reports First Quarter 2024 Financial Results and Provides Recent Business HighlightsGlobeNewswireUpdated interim data from the upliFT-D trial in FTD-GRN demonstrated that Dose 1 PBFT02 achieved consistent elevation of CSF progranulin at six months post-treatment in the two patients with longest follow-upCompleted
2y agoPASGPassage Bio to Present at Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing SummitGlobeNewswirePHILADELPHIA, April 22, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ:PASG), a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced
2y agoPASGPassage Bio Seeks Pennsylvania College Student Candidates for Third Annual Tachi Yamada Scholarship ProgramGlobeNewswire$10,000 scholarship to be awarded to a rising junior with a life science major attending a Pennsylvania-based four-year college or university Scholarship application deadline is April 26 for the initial award in the fall
2y agoPASGPassage Bio Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Recent Business HighlightsGlobeNewswireContinued momentum in upliFT-D trial of PBFT02 for the treatment of patients with frontotemporal dementia (FTD) with granulin mutations (GRN) with clinical trial site expansion into Europe and seven global sites now
2y agoPASGPassage Bio to Participate in Upcoming Investor ConferencesGlobeNewswirePHILADELPHIA, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ:PASG), a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced
2y agoPASGPassage Bio to Present at Guggenheim Healthcare Talks 6th Annual Biotechnology ConferenceGlobeNewswirePHILADELPHIA, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ:PASG), a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced
2y agoPASGPassage Bio Announces Promising Initial Data From Phase 1/2 Clinical Trial of PBFT02 in FTD-GRN and Updated Strategic PrioritiesGlobeNewswireDose 1 of PBFT02 achieved supraphysiologic CSF progranulin levels in each of the first three treated patients at 30 days after treatmentElevated progranulin levels were sustained at up to six months post-treatmentDose 1
2y agoPASGPassage Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)GlobeNewswirePHILADELPHIA, Nov. 17, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ:PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders,
2y agoPASGPassage Bio Reports Third Quarter 2023 Financial Results and Provides Recent Business HighlightsGlobeNewswireOn track to present initial safety and biomarker data from three Cohort 1 patients in global Phase 1/2 upliFT-D trial of PBFT02 for the treatment of patients with frontotemporal dementia (FTD) with granulin mutations
3y agoPASGPassage Bio to Present at Guggenheim's 5th Annual Inflammation, Neurology & Immunology ConferenceGlobeNewswirePHILADELPHIA, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ:PASG), a clinical stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders,
3y agoPASGPassage Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswirePHILADELPHIA, Oct. 20, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ:PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders,
3y agoPASGPassage Bio to Present at Chardan's 7th Annual Genetic Medicines ConferenceGlobeNewswirePHILADELPHIA, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ:PASG), a clinical stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders,
3y agoPASGPassage Bio Reports Second Quarter 2023 Financial Results and Provides Recent Business HighlightsGlobeNewswireReported promising interim data from Cohorts 1-4 in the Imagine-1 clinical trial for GM1 gangliosidosis (GM1); PBGM01 continued to have a favorable safety profile and dose-dependent effects on key CSF biomarkersDose 2 of
3y agoPASGPassage Bio Announces Promising Interim Clinical Data from First Eight Patients with GM1 Gangliosidosis in Imagine-1 StudyGlobeNewswireInterim safety data up to 28 months showed Dose 1 and 2 of PBGM01 were well tolerated and had a favorable safety and immunological profileDose 2 resulted in substantial improvements in key CSF biomarkers and was able to
3y agoPASGPassage Bio to Participate in Upcoming Investor ConferencesGlobeNewswirePHILADELPHIA, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ:PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders,
3y agoPASGPassage Bio Welcomes Dolan Sondhi, Ph.D. to Board Of DirectorsGlobeNewswirePHILADELPHIA, July 31, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ:PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS)
3y agoPASGPassage Bio to Present at Goldman Sachs 44th Annual Global Healthcare ConferenceGlobeNewswirePHILADELPHIA, June 05, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ:PASG), a clinical stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders,
3y agoPASGPassage Bio Reports First Quarter 2023 Financial Results and Provides Recent Business HighlightsGlobeNewswireOn track to report interim clinical data for two lead programs, PBGM01 for GM1 gangliosidosis and PBFT02 for frontotemporal dementia (FTD), in 2023Submitted protocol amendment to regulatory authorities for Imagine-1
3y agoPASGPassage Bio Announces Recipient of Second Annual Tachi Yamada Scholarship AwardGlobeNewswirePHILADELPHIA, May 04, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ:PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, has
3y agoPASGPassage Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswirePHILADELPHIA, April 21, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ:PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders,
3y agoPASGPassage Bio to Present at Chardan's 7th Annual Genetic Medicines and Cell Therapy Manufacturing SummitGlobeNewswirePHILADELPHIA, April 17, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ:PASG), a clinical stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders,